Easton Pharmaceuticals Signs "Viorra" Distribution Deal for Mexico

TORONTO, ON--(Marketwired - April 14, 2014) - Easton Pharmaceuticals (OTC: EAPH) is pleased to announce that BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products have signed an exclusive agreement to distribute Easton's "VIORRA" product in Mexico.

Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica, as previously announced, is the company's current regulatory consultant for Mexico and other parts of Latin America. After extensive discussions Easton has finalized a deal whereby BMV Medica will take over Marketing and Distribution for VIORRA." Mrs. Pepe further commented, "They have shown a strong interest in the growth of VIORRA in Mexico, and expect to launch VIORRA later this year, subject to the regulatory approvals and finalizing the sourcing out of a suitable manufacturing partner. Discussions with possible manufacturers are well under way and BMV anticipates finalizing a deal shortly."

Ms. Mendoza Vazquez, of BMV Medica, stated, "BMV has launched several products in Mexico recently, including pregnancy tests, and several antibiotics. BMV is pleased to have obtained the distribution rights to market and sell VIORRA in Mexico. Our market analysis reveals, of the overall 120 million population within Mexico, the potential VIORRA demographic could reach into the tens of millions of women." Ms. Vazquez further commented, "We have structured what we believe is a well-thought out marketing plan which includes spokespersons, retail channels, and online sales to ensure coverage across all sectors of the market. VIORRA will be marketed as a premium, feminine daily-use product, and we expect it to perform very well."

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various industries including medical marijuana that also owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues related towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company is also endeavoring to enter other potentially lucrative industries such as medical marijuana. The company's gel formulation is thought to be an innovative and unique transdermal delivery system. Easton Pharmaceuticals' product "VIORRA" is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which is believed to have a positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder); the world market for these female conditions is conservatively estimated to be in the billions. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in what the company had originally intended. Any investment made into Easton Pharmaceuticals would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.